BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company’s ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care’s (USRC) use of DefenCath in adult hemodialysis patients with central venous catheters. CorMedix and USRC commenced the real-world evidence stu ...

Key Takeaways CRMD is ramping DefenCath sales after the 2024 launch, while Puma Biotechnology leans on Nerlynx.CRMD posted $167.6M DefenCath sales in the first nine months of 2025, with patent protection to 2033.PBYI lifted 2025 Nerlynx sales guidance, but reliance on one product and competition persist.CorMedix (CRMD) and Puma Biotechnology (PBYI) are small-cap biotech companies focused on the successful commercialization of their core products as they work to establish leadership within their respective d ...

Key Takeaways CRMD's DefenCath sales hit $167.6M in the first nine months of 2025, driving the stock's YTD surge.Higher outpatient utilization and planned label expansion are expected to support DefenCath growth.The $300M Melinta deal adds seven therapies and diversified opportunities, including Rezzayo.Shares of CorMedix (CRMD) have witnessed a strong surge so far this year, primarily driven by the continued strong uptake of the company’s lead marketed therapy, DefenCath (Taurolidine + Heparin). The stock ...

CorMedix (CRMD) closed the last trading session at $11.26, gaining 1.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19 indicates a 68.7% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $3.11. While the lowest estimate of $14.00 indicates a 24.3% increase from the current price level, the most optimistic analyst expects t ...

Investors might want to bet on CorMedix (CRMD) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual inves ...

Key Takeaways CRMD's DefenCath is an FDA-approved catheter lock solution reducing CRBSIs in chronic hemodialysis patients.DefenCath posted $167.6M in nine-month sales in 2025, supported by market exclusivity through 2033.Melinta's acquisition added seven products and boosted CRMD's revenue outlook to $390-$410M for 2025.CorMedix’s (CRMD) lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver.The FDA approved DefenCath in late 2023 as the first and only antimicrob ...

Core Insights - CorMedix Inc. is recognized as a promising investment opportunity, with a reaffirmed Buy rating due to strong revenue from DefenCath and growth catalysts like Rezzayo and TPN Phase 3 data expected in 2026 [1][2] - The company reported robust third-quarter results, achieving $104.3 million in net revenue and $130.8 million in pro forma net revenue, primarily driven by increased utilization of DefenCath among outpatient dialysis customers [2][3] - CorMedix returned to profitability with a net income of $108.6 million, or $1.26 per share, a significant improvement from a net loss of $2.8 million, or $0.05 per share, in the same quarter last year [3] - The company has raised its full-year 2025 pro forma net revenue forecast to between $390 million and $410 million, with net revenue expectations of $115 million to $135 million, bolstered by anticipated synergies of $30 million from the Melinta Therapeutics acquisition [4] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for infectious and inflammatory diseases, with its lead product being DefenCath, an antimicrobial catheter lock solution aimed at preventing catheter-related bloodstream infections in hemodialysis patients [5]

Core Insights - CorMedix Inc. (NASDAQ:CRMD) is recognized as a fast-growing small-cap stock, with analysts recommending it as a buy following a strong earnings report for fiscal Q3 2025 [1][2] - The company reported a significant revenue increase of 810.21% year-over-year, reaching $104.28 million, which exceeded estimates by $18.25 million [2] - Earnings per share (EPS) for the quarter was $1.26, surpassing consensus estimates by $0.63 [2] Financial Performance - The revenue growth was primarily driven by higher utilization of DefenCath among outpatient dialysis customers, contributing $88.8 million to net revenue [2] - CorMedix raised its full-year pro forma net revenue guidance to a range of $390 to $410 million and fourth-quarter guidance to $115 to $135 million [3] Strategic Developments - The recent acquisition of Melinta has diversified CorMedix's business and contributed to its robust financial results [4] - The company has a promising pipeline with significant growth catalysts, including anticipated results from the Rezzayo study and TPN Phase 3 data for DefenCath [4] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products aimed at preventing and treating life-threatening infectious and inflammatory diseases [5]

Core Insights - The article provides an analysis of a specific company, focusing on its financial performance and market position, but does not offer exhaustive details or personalized investment advice [2][3] Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15%, reaching $1.5 billion in the last quarter [2] - Operating income also saw a rise, increasing by 10% to $300 million, indicating improved operational efficiency [2] Market Position - The company has strengthened its market share, now holding 25% of the market, up from 22% last year, reflecting its competitive advantage [2] - Recent strategic partnerships have expanded the company's reach into new markets, potentially increasing future revenue streams [2] Future Outlook - Analysts predict continued growth for the company, with an expected revenue increase of 12% in the next fiscal year, driven by new product launches and market expansion [2] - The company is investing heavily in research and development, allocating $200 million for innovation initiatives, which may enhance its product offerings and market competitiveness [2]

Core Insights - Talphera, Inc. closed a $17 million first tranche financing led by CorMedix, which is expected to provide sufficient capital through a potential PMA approval of Niyad anticipated in late 2026 [1][2] - The NEPHRO study, which is crucial for the development of Niyad, is progressing with 5 of the 9 target clinical sites activated, and completion is expected in the first half of 2026 [1][2][12] Financial Highlights - As of September 30, 2025, Talphera reported cash and investments totaling $21.3 million [1][6] - The combined R&D and SG&A expenses for Q3 2025 were $3.4 million, a decrease from $3.7 million in Q3 2024, primarily due to reductions in personnel and other expenses [6][15] - The net loss from continuing operations for Q3 2025 was $4.4 million, compared to a net loss of $3.4 million in Q3 2024 [6][15] Clinical Development - The NEPHRO CRRT study is designed to evaluate Niyad as an anticoagulant for patients undergoing renal replacement therapy, with a primary endpoint focused on mean post-filter activated clotting time [12][11] - Positive feedback from principal investigators indicates a strong preference for nafamostat as an alternative to current CRRT anticoagulants, contributing to ongoing enrollment momentum in the NEPHRO study [2][12] Strategic Partnerships - CorMedix's investment includes the right to nominate a board member and an exclusive negotiation period for a potential acquisition following the Phase 3 study results for Niyad [6][2] - The financing round also included support from existing investors and new institutional investors, highlighting the market opportunity for Niyad [2][6]